Contact:Consumer:(866) 891-1984Media:(224) 212-2357 FOR IMMEDIATE RELEASE - LAKE FOREST, Ill., - Oct. 18, 2013 - Hospira, Inc. (NYSE: HSP), announced today it will initiate a voluntary nationwide recall to the user level for one lot of 0.25% Marcaine™ (Bupivacaine HCl Injection, USP), 75 mg/30 mL, Single-dose Vial – Preservative Free (NDC 0409-1559-30), Lot 25-220-DD. The recall is due to a confirmed customer report of discolored solution with visible particles inside the glass vial as well as embedded in the glass. The embedded particulate was identified as iron oxide measuring approximately 3mm in diameter. To date, Hospira has not received reports of any adverse events associated with this issue for this lot. Hospira has attributed the embedded particulate to a supplier's glass defect. As a result of this issue we are working with our supplier on implementing corrective and preventive actions.If the particulate goes undetected and solution is administered, the particle may potentially block the infusion of the solution to the patient, resulting in a delay in therapy. Iron particulate may put a patient at risk from MRI (strong magnetic field exposure) as metal particulate, could potentially dislodge and be pulled through tissue causing inflammation and tissue trauma. The administration of an injectable with the presence of foreign particulates may potentially cause thrombophlebitis, bacteremia, sepsis, and/or endocarditis and death may result. Signs and symptoms could include redness, pain, swelling at the site, fever, shortness of breath, tachycardia, nausea, and vomiting.Marcaine is packaged 10 units per carton/100 units per case in glass fliptop vials. The impacted lot of Marcaine was distributed August 2013 through October 2013 to wholesalers/distributors, hospitals and pharmacies.Anyone with an existing inventory should immediately stop use and quarantine any affected product and return the product to Stericycle. For additional assistance, call Stericycle at 1-866-891-1984 between 8 a.m. and 5 p.m., ET, Monday through Friday.For clinical inquiries, please contact Hospira using the information provided below.Hospira ContactContact InformationAreas of SupportHospira Global Complaint Management1-800-441-4100 (8am-5pm CT, M-F) (ProductComplaintsPP@hospira.com)To report adverse events or product complaintsHospira Medical Communications1-800-615-0187 or email@example.com (Available 24 hours a day/7 days per week)Medical inquiriesAny adverse reactions or quality problems experienced with the use of this product may be reported to the U.S. Food and Drug Administration's (FDA) MedWatch Adverse Events Program either online, by regular mail or by fax.Online: www.fda.gov/medwatch/report.htmRegular mail: use postage-paid, pre-addressed Form FDA3500 available atwww.fda.gov/MedWatch/getforms.htmFax: 1-800-FDA-0178This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.About HospiraHospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 16,000 employees. Learn more at www.hospira.com.
Go back to list